CD28 and acute myeloid leukemia: In this study, we found that the high-risk group showed higher expression level of ICPs including CD28, CTLA4, TIGIT, PDCD1(PD-1) and PDCD1LG2(PD-L2), which may contribute to the inhibiting immunologic microenvironment in AML.